Progress of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of operable non-small cell lung cancer / 肿瘤研究与临床
Cancer Research and Clinic
;
(6): 476-480, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-996260
ABSTRACT
Patients with operable non-small cell lung cancer (NSCLC) receiving neoadjuvant or adjuvant chemotherapy have a very limited improvement in 5-year survival rate. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have made a breakthrough in the treatment of EGFR-mutant advanced NSCLC, which shed light for the exploration of perioperative targeted therapy in NSCLC patients. Significant progress has been made in the research of targeted therapy of the first and third generation EGFR-TKI in perioperative patients. The availability of novel potent and less toxic targeted therapy has brought new treatments for the operable NSCLC. This article reviews the progress and existing problems of adjuvant and neoadjuvant targeted therapy in NSCLC harboring EGFR mutation.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Cancer Research and Clinic
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS